Department of Neurosurgery, Medical Faculty, University of Duisburg-Essen, Hufelandstraße 55, 45122 Essen, Germany.
J Clin Neurosci. 2011 Nov;18(11):1495-9. doi: 10.1016/j.jocn.2011.02.044. Epub 2011 Sep 15.
The T393C polymorphism of the GNAS1 locus, which encodes the Gαs protein, has recently been found to be associated with patient outcome in various malignancies. We investigated the association between GNAS1 genotype and survival among patients suffering from glioblastoma multiforme (GBM). One hundred and sixty-two patients with GBM were retrospectively investigated. Inclusion criteria were availability of DNA and, for surviving patients, a follow-up of at least 24 months. The results were analysed based on clinical data, type of surgical intervention, adjuvant therapy, and 2-year survival. At the 2-year follow up, 79.6% of patients had died. Two-year survival rates were as follows: CC-homozygous patients, 15.8%; CT-heterozygous patients, 23.1%; and TT-homozygous patients, 18.2% (p = 0.461). Subgroup analysis revealed different 2-year survival rates in the group that underwent stereotactic biopsy, with 0% for CC-homozygous, 2.8% for CT-heterozygous, and 15.4% survival for TT-homozygous patients, but the differences were not statistically significant (p = 0.229). Our results indicate that there is no association between the GNAS1 T393C polymorphism and 2-year survival among patients with GBM.
GNAS1 基因座的 T393C 多态性，编码 Gαs 蛋白，最近被发现与多种恶性肿瘤患者的预后相关。我们研究了 GNAS1 基因型与多形性胶质母细胞瘤（GBM）患者生存之间的关系。对 162 例 GBM 患者进行了回顾性研究。纳入标准为 DNA 可用性，以及对存活患者进行至少 24 个月的随访。结果根据临床数据、手术干预类型、辅助治疗和 2 年生存率进行分析。在 2 年随访时，79.6%的患者死亡。2 年生存率如下：CC 纯合子患者为 15.8%；CT 杂合子患者为 23.1%；TT 纯合子患者为 18.2%（p=0.461）。亚组分析显示，接受立体定向活检的患者 2 年生存率不同，CC 纯合子患者为 0%，CT 杂合子患者为 2.8%，TT 纯合子患者为 15.4%，但差异无统计学意义（p=0.229）。我们的结果表明，GBM 患者 GNAS1 T393C 多态性与 2 年生存率之间没有关联。
